Shire Aims To Expand Vyvanse Binge Eating Claim With Maintenance Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to submit sNDA for maintenance of efficacy by year-end 2015 based on randomized withdrawal study evaluating time to relapse and 12-month open-label safety extension study.
You may also be interested in...
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials
The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.